Tetracaine
| 證據等級: L5 | 預測適應症: 9 個 |
目錄
Tetracaine: From Local Anesthesia to Acrodermatitis Chronica Atrophicans
One-Sentence Summary
Tetracaine is an ester-type local anesthetic classically used for surface, spinal, and mucous membrane anesthesia in ophthalmological, dental, and procedural settings. The TxGNN model predicts it may be effective for Acrodermatitis Chronica Atrophicans, with 0 clinical trials and 0 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Local anesthesia (surface, spinal, and mucous membrane anesthesia) |
| Predicted New Indication | Acrodermatitis Chronica Atrophicans |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| Philippines Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacology, Tetracaine is an ester-type local anesthetic that reversibly blocks voltage-gated sodium channels (Nav), suppressing nerve impulse conduction and producing localized sensory blockade. This mechanism underlies its use across ophthalmology, bronchoscopy pre-medication, spinal anesthesia, and procedural dermatology.
Acrodermatitis chronica atrophicans (ACA) is a late-stage dermatological manifestation of Borrelia burgdorferi infection (Lyme disease), characterized by progressive skin atrophy with an inflammatory prodrome that requires antibiotic therapy. The sodium channel-blocking mechanism of Tetracaine has no established pathway relevant to infectious or immune-mediated skin pathology. The TxGNN high score (99.93%) most likely reflects structural clustering of skin-related disease nodes in the knowledge graph rather than a genuine mechanistic connection.
It is worth noting that among all nine predicted indications in this evidence pack, acne keloid (Rank 5) carries the strongest clinical evidence: a completed Phase 4 double-blind RCT (NCT02372786, n=30) documented efficacy of a 7% lidocaine/7% tetracaine compound cream for procedural pain control during laser treatment of acne keloidalis nuchae. This is an extension of Tetracaine’s established local anesthetic use into a specific procedural context — not disease-modifying repurposing — but represents the most clinically actionable signal in this pack. Additionally, cauda equina syndrome (Rank 8) carries a critical reverse signal: all 9 associated publications document tetracaine-induced neurotoxicity following spinal administration, and must be interpreted as a safety warning, not a treatment opportunity.
Clinical Trial Evidence
Currently no related clinical trials registered for acrodermatitis chronica atrophicans.
Literature Evidence
Currently no related literature available for acrodermatitis chronica atrophicans.
Safety Considerations
Please refer to the package insert for safety information.
⚠️ Reverse Safety Signal — Cauda Equina Syndrome (Rank 8): Nine published case reports, follow-up studies, and mechanistic reviews consistently document tetracaine-induced cauda equina syndrome following spinal anesthesia. High-concentration intrathecal tetracaine can cause irreversible sodium channel blockade leading to persistent sacral sensory deficits and neurological injury. This pattern represents a known adverse event signal, not a repurposing candidate, and should be flagged as a contraindication to intrathecal high-dose administration.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked TxGNN prediction for acrodermatitis chronica atrophicans (L5, Score 99.93%) is unsupported by any clinical or preclinical evidence, and the mechanistic link between sodium channel blockade and Borrelia-driven late-stage Lyme skin disease is biologically implausible without further investigation. The most credible repurposing signal in this evidence pack — Tetracaine as procedural analgesia in acne keloid laser therapy (Rank 5, L1) — is an application of its existing local anesthetic indication and does not constitute novel disease-modifying repurposing.
To proceed, the following is needed:
- MOA data: Retrieve full mechanism of action from DrugBank API (DG002; High severity)
- Safety package: Download and parse the TFDA/Philippine FDA package insert for warnings and contraindications (DG001; Blocking — required before any S1 safety screening)
- Philippines regulatory pathway: Confirm whether any tetracaine-containing combination products (e.g., lidocaine/tetracaine cream) are registered or eligible for expedited review in the Philippines
- ACA mechanistic hypothesis: If ACA repurposing is to be seriously explored, preclinical data examining Nav modulation in Borrelia-driven inflammation or neuropathic skin pain would be required as a first step
- Acne keloid translation: If pivoting to the Rank 5 acne keloid procedural indication, a regulatory feasibility assessment for the 7% lidocaine/7% tetracaine combination in the Philippine market would be the appropriate next action
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.